NCT04308395 2024-09-24Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)Sol-Gel Technologies, Ltd.Phase 3 Terminated108 enrolled 12 charts
NCT03703310 2024-07-03Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas (BCCs) in Subjects With Basal Cell Nevus Syndrome (Gorlin Syndrome)Sol-Gel Technologies, Ltd.Phase 3 Completed174 enrolled 23 charts